ストックスクリーナーアプリを入手
6.79
1.16%
-0.08
プレマーケット:
6.84
0.05
+0.74%
前日終値:
$6.87
開ける：
$6.8
24時間の取引高:
33,556
Relative Volume:
0.57
時価総額：
$24.38M
収益：
-
当期純損益:
$-31.11M
株価収益率:
-4.4379
EPS:
-1.53
ネットキャッシュフロー:
$-28.18M
1週間 パフォーマンス:
+1.80%
1か月 パフォーマンス:
+9.16%
6か月 パフォーマンス:
-45.96%
1年 パフォーマンス:
-84.08%
1日の値動き範囲:
$6.50
$6.9757
1週間の範囲:
$6.2506
$6.9757
52週間の値動き範囲:
$5.3495
$47.45
Tempest Therapeutics Inc Stock (TPST) Company Profile
名前
Tempest Therapeutics Inc
セクター
電話
415-798-8589
住所
2000 SIERRA POINT PARKWAY, BRISBANE
TPST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
6.79 | 24.38M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-02-08 | 開始されました | Jefferies | Buy |
Tempest Therapeutics Inc (TPST) 最新ニュース
Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan
Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com
Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times
Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq
Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire
Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan
Tempest Therapeutics regains Nasdaq compliance - Investing.com
Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX
Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times
Tempest to explore alternatives to advance promising pipeline - The Pharma Letter
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN
Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive
HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com
Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News
Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa
Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks
Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com
Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com
Tempest Therapeutics evaluates strategic options amid advancements - Investing.com
Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire
Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia
Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada
Tempest Therapeutics Announced 1-For-13 Reverse Stock Split - marketscreener.com
Top Analysts Slash Price Targets for Meta Platforms Stock (META) on Macro and Tariff Concerns - The Globe and Mail
TPST stock touches 52-week low at $0.69 amid market challenges - Investing.com Canada
TPST stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):